85 related articles for article (PubMed ID: 25569716)
1. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.
Nie Z; Du MQ; McAllister-Lucas LM; Lucas PC; Bailey NG; Hogaboam CM; Lim MS; Elenitoba-Johnson KS
Nat Commun; 2015 Jan; 6():5908. PubMed ID: 25569716
[TBL] [Abstract][Full Text] [Related]
2. Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
Wimberger N; Ober F; Avar G; Grau M; Xu W; Lenz G; Menden MP; Krappmann D
Blood; 2023 Dec; 142(23):1985-2001. PubMed ID: 37623434
[TBL] [Abstract][Full Text] [Related]
3. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis.
Stoffel A; Chaurushiya M; Singh B; Levine AJ
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9079-84. PubMed ID: 15184680
[TBL] [Abstract][Full Text] [Related]
4. The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.
Rosebeck S; Rehman AO; Apel IJ; Kohrt D; Appert A; O'Donnell MA; Ting AT; Du MQ; Baens M; Lucas PC; McAllister-Lucas LM
Oncogene; 2014 May; 33(19):2520-30. PubMed ID: 23770847
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) induces ferroptosis in vascular smooth muscle cells.
Yan B; Belke D; Gui Y; Chen YX; Jiang ZS; Zheng XL
Cell Death Discov; 2023 Dec; 9(1):456. PubMed ID: 38097554
[TBL] [Abstract][Full Text] [Related]
6. MALT1-ubiquitination triggers non-genomic NF-κB/IKK signaling upon platelet activation.
Karim ZA; Vemana HP; Khasawneh FT
PLoS One; 2015; 10(3):e0119363. PubMed ID: 25748427
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.
Bornancin F; Renner F; Touil R; Sic H; Kolb Y; Touil-Allaoui I; Rush JS; Smith PA; Bigaud M; Junker-Walker U; Burkhart C; Dawson J; Niwa S; Katopodis A; Nuesslein-Hildesheim B; Weckbecker G; Zenke G; Kinzel B; Traggiai E; Brenner D; Brüstle A; St Paul M; Zamurovic N; McCoy KD; Rolink A; Régnier CH; Mak TW; Ohashi PS; Patel DD; Calzascia T
J Immunol; 2015 Apr; 194(8):3723-34. PubMed ID: 25762782
[TBL] [Abstract][Full Text] [Related]
8. Detection of recombinant and cellular MALT1 paracaspase activity.
Nagel D; Krappmann D
Methods Mol Biol; 2015; 1280():239-46. PubMed ID: 25736752
[TBL] [Abstract][Full Text] [Related]
9. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation.
Punwani D; Wang H; Chan AY; Cowan MJ; Mallott J; Sunderam U; Mollenauer M; Srinivasan R; Brenner SE; Mulder A; Claas FH; Weiss A; Puck JM
J Clin Immunol; 2015 Feb; 35(2):135-46. PubMed ID: 25627829
[TBL] [Abstract][Full Text] [Related]
10. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
[TBL] [Abstract][Full Text] [Related]
11. Research funding. Big names or big ideas: do peer-review panels select the best science proposals?
Li D; Agha L
Science; 2015 Apr; 348(6233):434-8. PubMed ID: 25908820
[TBL] [Abstract][Full Text] [Related]
12. A glaring paradox.
Johnston M
Genetics; 2015 Mar; 199(3):637-8. PubMed ID: 25740911
[No Abstract] [Full Text] [Related]
13. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
14. EPLIN is a crucial regulator for extrusion of RasV12-transformed cells.
Ohoka A; Kajita M; Ikenouchi J; Yako Y; Kitamoto S; Kon S; Ikegawa M; Shimada T; Ishikawa S; Fujita Y
J Cell Sci; 2015 Feb; 128(4):781-9. PubMed ID: 25609711
[TBL] [Abstract][Full Text] [Related]
15. MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses.
Yu JW; Hoffman S; Beal AM; Dykon A; Ringenberg MA; Hughes AC; Dare L; Anderson AD; Finger J; Kasparcova V; Rickard D; Berger SB; Ramanjulu J; Emery JG; Gough PJ; Bertin J; Foley KP
PLoS One; 2015; 10(5):e0127083. PubMed ID: 25965667
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.
Arribas AJ; Rinaldi A; Mensah AA; Kwee I; Cascione L; Robles EF; Martinez-Climent JA; Oscier D; Arcaini L; Baldini L; Marasca R; Thieblemont C; Briere J; Forconi F; Zamò A; Bonifacio M; Mollejo M; Facchetti F; Dirnhofer S; Ponzoni M; Bhagat G; Piris MA; Gaidano G; Zucca E; Rossi D; Bertoni F
Blood; 2015 Mar; 125(12):1922-31. PubMed ID: 25612624
[TBL] [Abstract][Full Text] [Related]
17. Clustering of CARMA1 through SH3-GUK domain interactions is required for its activation of NF-κB signalling.
Hara H; Yokosuka T; Hirakawa H; Ishihara C; Yasukawa S; Yamazaki M; Koseki H; Yoshida H; Saito T
Nat Commun; 2015 Jan; 6():5555. PubMed ID: 25602919
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection.
Chao C; Silverberg MJ; Xu L; Chen LH; Castor B; Martínez-Maza O; Abrams DI; Zha HD; Haque R; Said J
Clin Cancer Res; 2015 Mar; 21(6):1429-37. PubMed ID: 25589617
[TBL] [Abstract][Full Text] [Related]
19. API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.
Rosebeck S; Lim MS; Elenitoba-Johnson KS; McAllister-Lucas LM; Lucas PC
World J Biol Chem; 2016 Feb; 7(1):128-37. PubMed ID: 26981201
[TBL] [Abstract][Full Text] [Related]
20. MALT1 is not alone after all: identification of novel paracaspases.
Hulpiau P; Driege Y; Staal J; Beyaert R
Cell Mol Life Sci; 2016 Mar; 73(5):1103-16. PubMed ID: 26377317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
